TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial
Titel:
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial
Auteur:
Zaanan, Aziz Bouché, Olivier de la Fouchardière, Christelle Le Malicot, Karine Pernot, Simon Louvet, Christophe Artru, Pascal Le Brun Ly, Valérie Aldabbagh, Kais Khemissa-Akouz, Faiza Lecomte, Thierry Castanie, Hélène Laly, Margot Botsen, Damien Roth, Gael Samalin, Emmanuelle Muller, Marie Breysacher, Gilles Manfredi, Sylvain Phelip, Jean-Marc Taieb, Julien